Quantcast
Home > Quotes > ACRX
ACRX

AcelRx Pharmaceuticals, Inc. Common Stock (ACRX) Quote & Summary Data

$2.37
*  
0.03
1.28%
Get ACRX Alerts
*Delayed - data as of Jun. 18, 2019 13:51 ET  -  Find a broker to begin trading ACRX now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    ACRX Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 2.36 / $ 2.37
Today's High / Low
$ 2.40 / $ 2.31
Share Volume
567,833
50 Day Avg. Daily Volume
1,463,219
Previous Close
$ 2.34
52 Week High / Low
$ 5.05 / $ 1.99
Market Cap
187,026,583
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
567,833
50 Day Avg. Daily Volume:
1,463,219

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.76

Trading Range

The current last sale of $2.37 is 19.10% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 2.40 $ 5.05
 Low: $ 2.31 $ 1.99

Company Description (as filed with the SEC)

We are a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. DSUVIA(TM) (known as DZUVEO in Europe) and Zalviso, are both focused on the treatment of acute pain, and each utilize sufentanil, delivered via a non-invasive route of sublingual administration, exclusively for use in medically supervised settings. On November 2, 2018, the U.S. Food and Drug Administration, or FDA, approved our resubmitted NDA for DSUVIA for use in adults in certified medically supervised healthcare settings, such as hospitals, surgical centers, and emergency departments, for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. In June 2018, the European Commission, or EC, granted marketing approval of DZUVEO for the treatment of patients with moderate-to-severe acute pain in medically monitored settings.  ... More ...  



Risk Grade

Where does ACRX fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 2.35
Open Date:
Jun. 18, 2019
Close Price:
$ 2.34
Close Date:
Jun. 17, 2019


Consensus Recommendation

Analyst Info